The regulatory approval of this compound was based on the results of the Emilia study, a phase III randomized controlled trial which assessed the PFS and the OS of 991 patients with locally unresectable or metastatic HER2-positive breast cancer treated with T-DM1 vs capecitabine-lapatinib. This evidence concerns the gene ERBB2 and breast carcinoma.